BACKGROUND: Previous studies have reported a poor outcome for synovial sarcoma patients whose tumours relapse. METHODS: This study analysed 44 relapsing cases in a series of 118 consecutive patients <21 yr of age with non-metastatic synovial sarcoma prospectively enrolled in Italian paediatric protocols between 1979 and 2006. In an effort to identify a possible risk-adapted stratification enabling a better planning of second-line treatment, the relapsing patients' outcome was analysed vis-à-vis their clinical picture at onset, first-line treatments, clinical findings at the time of first relapse and second-line treatment modalities. RESULTS: The first event was a local recurrence in only 15 cases, and metastatic in 29 (associated with local relapse too in 7 cases). The time to relapse ranged from 4 to 108 months (median 20 months). Overall survival was 29.7% and 21.0% five and ten years after relapsing, respectively. The variables influencing survival were the timing and type of relapse (combined) and the chances of a secondary remission, which correlated strongly with the feasibility of complete surgery. CONCLUSIONS: Our study confirmed a largely unsatisfactory prognosis after recurrences in children and adolescents with synovial sarcoma: the chances of survival can be estimated on the basis of several variables for the purposes of planning risk-adapted salvage protocols. An aggressive surgical approach should be recommended. New effective systemic agents are warranted, and experimental therapies can be offered to patients with little chance of salvage.
BACKGROUND: Previous studies have reported a poor outcome for synovial sarcomapatients whose tumours relapse. METHODS: This study analysed 44 relapsing cases in a series of 118 consecutive patients <21 yr of age with non-metastatic synovial sarcoma prospectively enrolled in Italian paediatric protocols between 1979 and 2006. In an effort to identify a possible risk-adapted stratification enabling a better planning of second-line treatment, the relapsing patients' outcome was analysed vis-à-vis their clinical picture at onset, first-line treatments, clinical findings at the time of first relapse and second-line treatment modalities. RESULTS: The first event was a local recurrence in only 15 cases, and metastatic in 29 (associated with local relapse too in 7 cases). The time to relapse ranged from 4 to 108 months (median 20 months). Overall survival was 29.7% and 21.0% five and ten years after relapsing, respectively. The variables influencing survival were the timing and type of relapse (combined) and the chances of a secondary remission, which correlated strongly with the feasibility of complete surgery. CONCLUSIONS: Our study confirmed a largely unsatisfactory prognosis after recurrences in children and adolescents with synovial sarcoma: the chances of survival can be estimated on the basis of several variables for the purposes of planning risk-adapted salvage protocols. An aggressive surgical approach should be recommended. New effective systemic agents are warranted, and experimental therapies can be offered to patients with little chance of salvage.
Authors: A D Baheti; S H Tirumani; R Sewatkar; A B Shinagare; J L Hornick; N H Ramaiya; J P Jagannathan Journal: Br J Radiol Date: 2014-11-28 Impact factor: 3.039
Authors: Samer Salah; Sameer Yaser; Ahmed Salem; Abdellatif Al Mousa; Areej Abu Sheikha; Iyad Sultan Journal: Med Oncol Date: 2013-06-19 Impact factor: 3.064
Authors: C Moreau-Bachelard; L Campion; M Toulmonde; A Le Cesne; M Brahmi; A Italiano; O Mir; S Piperno-Neumann; V Laurence; N Firmin; N Penel; F Duffaud; C Chevreau; F Bertucci; B Narciso; P Dubray-Longeras; C Delcambre; E Saada-Bouzid; P Boudou-Rouquette; P Soulie; C Perrin; J Y Blay; E Bompas Journal: ESMO Open Date: 2022-02-21
Authors: Andrea Ferrari; Bernadette Brennan; Michela Casanova; Nadege Corradini; Pablo Berlanga; Reineke A Schoot; Gema L Ramirez-Villar; Akmal Safwat; Gabriela Guillen Burrieza; Patrizia Dall'Igna; Rita Alaggio; Lisa Lyngsie Hjalgrim; Susanne Andrea Gatz; Daniel Orbach; Max M van Noesel Journal: Cancer Manag Res Date: 2022-09-23 Impact factor: 3.602